All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The animal world is full of species that can perform astonishing, and sometimes disgusting, feats. Take vultures, for example. “They eat this rotten meat that is full of pathogens and toxins, and they stay healthy,” Neta Raab told BioWorld. Raab is the co-founder and CEO of Wild Biotech Ltd., an Israeli startup that is seeking to understand gut microbiome contributions to these animal superpowers, and harness them for therapeutic use.
The animal world is full of species that can perform astonishing, and sometimes disgusting, feats. Take vultures, for example. “They eat this rotten meat that is full of pathogens and toxins, and they stay healthy,” Neta Raab told BioWorld. Raab is the co-founder and CEO of Wild Biotech Ltd., an Israeli startup that is seeking to understand gut microbiome contributions to these animal superpowers, and harness them for therapeutic use.
Researchers at Duke University have developed a set of methods to separate out microbial contamination from microbiome species that were part of tumors and used those methods to gain new insights into tumor microbiomes.
Investigators at the National Institute of Allergy and Infectious Diseases have identified physiological factors that are not diseases in the narrow sense, but that nevertheless have large effects on microbiome composition.
"Microbiome" has become a health and wellness buzzword, implicated as a contributing factor in conditions ranging from diabetes and obesity to gastrointestinal disease, autoimmune diseases and even autism. But the tools scientists use to cultivate bacteria have changed little over the past century, says Peter Christey, founder and CEO of San Carlos, Calif.-based startup General Automation Lab Technologies Inc. (GALT). His firm is hoping to change that with a high-throughput system of hugely parallel arrays and high-resolution images of complex samples that will revolutionize the way microbiology laboratories process genetic material.
Synthetic biology is seeing rapid advances, but the medical applications have thus far remained largely elusive. But now researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have developed a tool that can track specific populations of bacteria in the gut of living organisms and document population changes over time.
BOSTON – The gut microbiome and its prospects for drug development have been matters of debate for a while, sharpened by the high-profile phase II failure of Seres Therapeutics Inc.'s candidate, SER-109, in the summer of 2016. A panel at Biopharm America surveyed the space in light of developments since the stumble with that candidate, composed of about 50 species of firmicutes spores derived from stool specimens from healthy donors, against recurrent Clostridium difficile infection.
The ultimate vision is pretty fantastical: A variety of synthetically engineered bacteria working together to diagnose – and even secrete proteins to treat – various inflammatory conditions or other immune-associated diseases. But researchers at the Wyss Institute at Harvard University and Harvard Medical School have taken another step along the path toward that goal.
RSS
